INDIVIOR UK LIMITED

• ◆

  4 officer resignations in last 12 months

  Multiple officers have left the board recently — see the People section for who.

Figures converted to GBP from USD at 0.743 per USD (Frankfurter spot rate) — hover any figure for the original. — indicates the figure wasn't present under that line item in that period. The Δ column is the change from the prior filed period as a percentage of |prior|; lines a company doesn't report show —. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

1. INDIVIOR UK LIMITED 2015-07-01 → present
2. RB PHARMACEUTICALS LIMITED 2010-03-09 → 2015-07-01

Accounting basis

FRS 102

Reporting scope

Standalone (parent only)

Auditor

PricewaterhouseCoopers LLP

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.”

Group structure

1. INDIVIOR UK LIMITED · parent
   1. Indivior España S.L.U. 100% · Spain · Operating company
   2. Indivior EU Limited 100% · England & Wales · Dormant Company
   3. Indivior Italia S.r.l. 100% · Italy · Operating Company
   4. Opiant Pharmaceuticals UK Limited 100% · England & Wales · Dormant Company
   5. Indivior UK Finance No 2 Limited 100% · England & Wales · Finance Company
   6. Indivior UK Finance No 3 Limited* 100% · England & Wales · Finance Company

Significant events

• “In August 2025, the Group announced a restructuring of the Research & Development and Medical Affairs organizations, which included the planned closure of one of Indivior UK Limited's locations.”
• “In October 2025, the Group announced its intent to cease operations and discontinue the sale of products in several markets, including the U.K., Ireland, Sweden, Israel, Finland, and Italy.”
• “In April 2026, the Group announced externally that INDV-6001 (buprenorphine-based ultra long-acting injectables) and has amended its license agreement with Alar Pharmaceuticals.”
• “In April 2026, the Group announced externally that INDV-2000 (oral Orexin-1 receptor antagonist) did not meet the primary endpoint of "no treatment failure."”
• “On January 23, 2026, Indivior Pharmaceuticals, Inc., a U.S. corporation formed on October 28, 2025 (Indivior Pharmaceuticals), became the ultimate parent company of Indivior Limited (formerly Indivior PLC), a public company limited by shares incorporated under the laws of England and Wales (Indivior Limited), and its subsidiaries.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

19

last 12 months

Capital events

0

last 24 months

Officers appointed

1

last 12 months

Officers resigned

4

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.